BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45:307-313. [PMID: 17256746 DOI: 10.1002/hep.21534] [Cited by in Crossref: 243] [Cited by in F6Publishing: 220] [Article Influence: 16.2] [Reference Citation Analysis]
Number Citing Articles
1 Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV;  GLOBE Study Group. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486-495. [PMID: 19027013 DOI: 10.1053/j.gastro.2008.10.026] [Cited by in Crossref: 412] [Cited by in F6Publishing: 394] [Article Influence: 29.4] [Reference Citation Analysis]
2 Kwon HC, Cheong JY, Cho SW, Choi JM, Hong SP, Kim SO, Yoo WD. Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. J Gastroenterol Hepatol 2009;24:49-54. [PMID: 19196395 DOI: 10.1111/j.1440-1746.2008.05570.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
3 Triolo M, Della Corte C, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int. 2014;34 Suppl 1:139-145. [PMID: 24373091 DOI: 10.1111/liv.12394] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
4 Si Ahmed SN, Zoulim F. Pathobiology of HBV mutants and clinical impact for treatment monitoring. Expert Review of Anti-infective Therapy 2014;7:309-20. [DOI: 10.1586/eri.09.10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
5 Tanaka M, Suzuki F, Seko Y, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol. 2014;49:470-480. [PMID: 23525978 DOI: 10.1007/s00535-013-0779-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
6 Chao DC, Hu KQ. Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther. 2013;7:777-788. [PMID: 23990707 DOI: 10.2147/dddt.s33947] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
7 Tsunoda SM, Hassanein T. Telbivudine for the treatment of hepatitis B disease. Future Virology 2008;3:517-27. [DOI: 10.2217/17460794.3.6.517] [Reference Citation Analysis]
8 Manolakopoulos S, Bethanis S, Koutsounas S, Goulis J, Vlachogiannakos J, Christias E, Saveriadis A, Pavlidis C, Triantos C, Christidou A, Papatheodoridis G, Karamanolis D, Tzourmakliotis D. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther 2008;27:266-73. [PMID: 17988233 DOI: 10.1111/j.1365-2036.2007.03567.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
9 Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J. Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World J Gastroenterol 2011; 17(24): 2945-2952 [PMID: 21734806 DOI: 10.3748/wjg.v17.i24.2945] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
10 Kim HJ, Cho JY, Kim YJ, Gwak GY, Paik YH, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med 2015;30:32-41. [PMID: 25589833 DOI: 10.3904/kjim.2015.30.1.32] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
11 Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ, Cho Y. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother. 2014;58:6710-6716. [PMID: 25155601 DOI: 10.1128/aac.03845-14aac.03845-14] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Lv J, Jin Q, Sun H, Chi X, Hu X, Yan H, Pan Y, Xiao W, Tian Z, Hou J. Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients. Mediators Inflamm. 2012;2012:804043. [PMID: 23304062 DOI: 10.1155/2012/804043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
13 Cho EY, Yim HJ, Jung YK, Suh SJ, Seo YS, Kim JH, Kim HS, Lee SH, Ahn SH, Lee JI, Jeong SH, Kim JW, Lee JW, Kim IH, Kim HS, Park SJ, Lee JM, Hwang SG; Antiviral Resistance Study Group. Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study. Gut Liver 2017;11:129-35. [PMID: 27538443 DOI: 10.5009/gnl15597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
14 Weisberg IS, Brown RS, Sigal SH. Hepatitis B and End-Stage Liver Disease. Clinics in Liver Disease 2007;11:893-916. [DOI: 10.1016/j.cld.2007.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
15 Yun TJ, Jung JY, Kim CH, Um SH, An H, Seo YS, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS. Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2012; 18(47): 6987-6995 [PMID: 23322998 DOI: 10.3748/wjg.v18.i47.6987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
16 Sun M, Tan G, Song J, Wang J, Wu X. Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B. Clin Res Hepatol Gastroenterol 2016;40:590-6. [PMID: 27016894 DOI: 10.1016/j.clinre.2016.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
17 Kim YS, Kim GH, Hwang YJ, Kwon OS, Choi DJ, Kim JH. Early development of clevudine resistance during clevudine therapy in a patient with chronic hepatitis B who received prior lamivudine therapy. Liver Int. 2009;29:950-951. [PMID: 19192171 DOI: 10.1111/j.1478-3231.2008.01967.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Chang TT, Suh DJ. Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatol Int 2008;2:19-27. [PMID: 19669295 DOI: 10.1007/s12072-008-9059-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
19 TrehanPati N, Kotillil S, Hissar SS, Shrivastava S, Khanam A, Sukriti S, Mishra SK, Sarin SK. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. J Clin Immunol. 2011;31:509-520. [PMID: 21305387 DOI: 10.1007/s10875-011-9509-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
20 Liu Y, Wang C, Zhong Y, Li X, Dai J, Ren X, Xu Z, Li L, Yao Z, Ji D, Wang L, Zhang L, Wong VW, Zoulim F, Xu D. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. J Viral Hepat 2011;18:e29-39. [PMID: 21392168 DOI: 10.1111/j.1365-2893.2010.01360.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
21 van der Poorten D, Prakoso E, Khoo TL, Ngu MC, McCaughan GW, Strasser SI, Lee AU. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. J Gastroenterol Hepatol. 2007;22:1500-1505. [PMID: 17683493 DOI: 10.1111/j.1440-1746.2007.05093.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
22 Cho SW, Cho YJ, Cheong JY, Lee MH, Jeon SJ, Lee YC, Lim SG, Kang CJ. [Add on lamivudine to adefovir monotherapy for the treatment of lamivudine-resistant chronic hepatitis B patients]. Korean J Gastroenterol 2010;56:83-9. [PMID: 20729619 DOI: 10.4166/kjg.2010.56.2.83] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
23 Ze E, Baek EK, Lee JJ, Chung HW, Ahn DG, Cho HJ, Kwon JC, Kim HJ, Lee H. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. Clin Mol Hepatol 2014;20:267-73. [PMID: 25320730 DOI: 10.3350/cmh.2014.20.3.267] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
24 Ahn SH, Kweon YO, Paik SW, Sohn JH, Lee KS, Kim DJ, Piratvisuth T, Yuen MF, Chutaputti A, Chao YC. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Hepatol Int. 2011;Oct 12; Epub ahead of print. [PMID: 21989925 DOI: 10.1007/s12072-011-9314-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
25 Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2008;28:167-177. [PMID: 18466358 DOI: 10.1111/j.1365-2036.2008.03731.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
26 Papatheodoridis GV. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. Liver Int. 2011;31 Suppl 1:95-103. [PMID: 21205145 DOI: 10.1111/j.1478-3231.2010.02392.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
27 Montagnani M, Giandinoto M, Lisotti A, Galli S, Azzaroli F, Buonfiglioli F, Turco L, Aldini R, Mazzella G. High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on. Dig Dis Sci 2012;57:561-7. [PMID: 21881973 DOI: 10.1007/s10620-011-1873-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM. Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience. Liver Int. 2011;31:206-214. [PMID: 21143368 DOI: 10.1111/j.1478-3231.2010.02416.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
29 Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ, Cho Y. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother. 2014;58:6710-6716. [PMID: 25155601 DOI: 10.1128/AAC.03845-14] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
30 Liu WX, Yang L, Yan HM, Yan LN, Zhang XL, Ma N, Tang LM, Gao X, Liu DW. Germline Variants and Genetic Interactions of Several EMT Regulatory Genes Increase the Risk of HBV-Related Hepatocellular Carcinoma. Front Oncol 2021;11:564477. [PMID: 34178612 DOI: 10.3389/fonc.2021.564477] [Reference Citation Analysis]
31 Yu R, Fan R, Hou J. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Front Med 2014;8:135-44. [PMID: 24810645 DOI: 10.1007/s11684-014-0331-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
32 Sherman M. Prevention of hepatocellular carcinoma: the holy grail of hepatitis B treatment. J Hepatol. 2009;50:854-856. [PMID: 19303162 DOI: 10.1016/j.jhep.2009.02.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Lok AS. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transpl. 2008;14 Suppl 2:S8-S14. [PMID: 18825720 DOI: 10.1002/lt.21616] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
34 Chen Y, Ju T. Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B. Int J Infect Dis 2012;16:e152-8. [PMID: 22226087 DOI: 10.1016/j.ijid.2011.11.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
35 Cho Y, Lee DH, Chung KH, Jin E, Lee J, Cho EJ, Yu SJ, Kim JW, Jeong SH, Yoon J, Lee H, Kim CY, Kim YJ. The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir. Dig Dis Sci 2013;58:1363-70. [DOI: 10.1007/s10620-012-2480-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
36 Ohishi W, Chayama K. Current treatment for chronic hepatitis B in Japan. Clin J Gastroenterol 2009;2:325-30. [DOI: 10.1007/s12328-009-0100-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
37 Reijnders JG, Janssen HL. Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J Hepatol. 2008;48:383-386. [PMID: 18191272 DOI: 10.1016/j.jhep.2007.12.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
38 Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010;25:1374-80. [PMID: 20659226 DOI: 10.1111/j.1440-1746.2010.06381.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
39 Gu EL, Yu YQ, Wang JL, Ji YY, Ma XY, Xie Q, Pan HY, Wu SM, Li J, Chen CW, Xu XW, Wang YE, Yao GB, Wang H, Zhang WH. Response-guided treatment of cirrhotic chronic hepatitis B patients: Multicenter prospective study. World J Gastroenterol 2015; 21(2): 653-660 [PMID: 25605989 DOI: 10.3748/wjg.v21.i2.653] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
40 Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29 Suppl 1:100-107. [PMID: 19207972 DOI: 10.1111/j.1478-3231.2008.01941.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 140] [Article Influence: 11.2] [Reference Citation Analysis]
41 Sánchez-tapias JM. Fármacos para el tratamiento de la hepatitis B crónica. Gastroenterología y Hepatología 2008;31:120-8. [DOI: 10.1157/13116500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Park MS, Kim BK, Kim KS, Kim JK, Kim SU, Park JY, Kim do Y, Baartarkhuu O, Han KH, Chon CY. Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. Clin Mol Hepatol. 2013;19:29-35. [PMID: 23593607 DOI: 10.3350/cmh.2013.19.1.29] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
43 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int. 2010;4:414-422. [PMID: 20305760 DOI: 10.1007/s12072-009-9162-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
45 Margeridon-Thermet S, Shafer RW. Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses. 2010;2:2696-2739. [PMID: 21243082 DOI: 10.3390/v2122696] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
46 Tamori A, Enomoto M, Kobayashi S, Iwai S, Morikawa H, Sakaguchi H, Habu D, Shiomi S, Imanishi Y, Kawada N. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat. 2010;17:123-129. [PMID: 19674281 DOI: 10.1111/j.1365-2893.2009.01160.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
47 Klein MB, Baril JG, Charron MA, Fortin C, Lalonde R, Matte MF, Poliquin M, Talbot A, Therrien R, Tremblay C, Trottier B, Tsarevsky I, Villeneuve JP. Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals. Can J Infect Dis Med Microbiol 2011;22:88-96. [PMID: 22942885 DOI: 10.1155/2011/686918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
48 Fok BS, Gardner S, Piscitelli S, Chen S, Chu TT, Chan JC, Tomlinson B. Pharmacokinetic Properties of Single-Dose Lamivudine/Adefovir Dipivoxil Fixed-Dose Combination in Healthy Chinese Male Volunteers. Clinical Therapeutics 2013;35:68-76. [DOI: 10.1016/j.clinthera.2012.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Manolakopoulos S, Striki A, Deutsch M, Mela M, Ketikoglou I, Tzourmakliotis D, Manesis EK, Papatheodoridis GV. Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Liver Int. 2011;31:1525-1532. [PMID: 22093327 DOI: 10.1111/j.1478-3231.2011.02616.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
50 Rodríguez M, González-Diéguez ML. [Clinical management of patients with chronic hepatitis B virus infection]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:56-65. [PMID: 19100232 DOI: 10.1016/s0213-005x(08)76520-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Wang F, Zhang J, Zhang XG, Zhang J, Li DM. Adefovir combined with lamivudine in treatment of lamivudine-resistant patients with decompensated liver cirrhosis: an analysis of 14 cases. Shijie Huaren Xiaohua Zazhi 2008; 16(13): 1468-1470 [DOI: 10.11569/wcjd.v16.i13.1468] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Zarski JP, Leroy V. [The patient with uncontrolled chronic hepatitis B]. Gastroenterol Clin Biol 2008;32:S7-11. [PMID: 18662613 DOI: 10.1016/S0399-8320(08)73259-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver International 2010;30:657-68. [DOI: 10.1111/j.1478-3231.2010.02207.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
54 Segovia MC, Chacra W, Gordon SC. Adefovir dipivoxil in chronic hepatitis B: history and current uses. Expert Opin Pharmacother 2012;13:245-54. [PMID: 22242973 DOI: 10.1517/14656566.2012.649727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
55 Freshwater DA, Dudley T, Cane P, Mutimer DJ. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation. 2008;85:1105-1111. [PMID: 18431229 DOI: 10.1097/tp.0b013e31816a342a] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
56 Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy. J Med Virol. 2013;85:55-64. [PMID: 23096938 DOI: 10.1002/jmv.23440] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
57 Toyama T, Ishida H, Ishibashi H, Yatsuhashi H, Nakamuta M, Shimada M, Ohta H, Satoh T, Kato M, Hijioka T, Takano H, Komeda T, Yagura M, Mano H, Watanabe Y, Kobayashi M, Mita E. Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B: Long-term outcomes of add-on ADV therapy. Hepatology Research 2012;42:1168-74. [DOI: 10.1111/j.1872-034x.2012.01038.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
58 Moriconi F, Colombatto P, Coco B, Ciccorossi P, Oliveri F, Flichman D, Maina AM, Sacco R, Bonino F, Brunetto MR. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. J Antimicrob Chemother. 2007;60:341-349. [PMID: 17567633 DOI: 10.1093/jac/dkm187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
59 Park YH, Kim BK, Kim JK, Kim HC, Kim DY, Park JY, Han K, Kim SU, Shin SH, Hahn KY, Ahn SH. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea: The outcomes of chronic hepatitis B. J Gastroenterol Hepatol 2014;29:1005-11. [DOI: 10.1111/jgh.12478] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
60 Yuen MF, Lai CL. Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol. 2011;26 Suppl 1:138-143. [PMID: 21199525 DOI: 10.1111/j.1440-1746.2010.06545.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 9.4] [Reference Citation Analysis]
61 Kim BG, Jung SW, Kim EH, Kim JH, Park JH, Sung SJ, Park BR, Kim M, Kim CJ, Lee BU, Park JH, Jeong ID, Bang S, Shin JW, Park NH. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir: Tenofovir in multidrug resistant hepatitis B. J Gastroenterol Hepatol 2015;30:1514-21. [DOI: 10.1111/jgh.12993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
62 Ren Y, Yang L, Li M, Wang J, Yan H, Ma N, Liu W, Wang L, Gao X, Gao P, Li T, Liu D. 4210 Da and 1866 Da polypeptides as potential biomarkers of liver disease progression in hepatitis B virus patients. Sci Rep 2021;11:16982. [PMID: 34417517 DOI: 10.1038/s41598-021-96581-4] [Reference Citation Analysis]
63 Zeng T, Xu H, Liu JY, Lei Y, Zhong S, Zhou Z. Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis. J Clin Pharmacol 2014;54:959-67. [PMID: 24964070 DOI: 10.1002/jcph.351] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
64 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
65 Kim JH, Park YK, Park ES, Kim KH. Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World J Gastroenterol 2014; 20(19): 5708-5720 [PMID: 24914332 DOI: 10.3748/wjg.v20.i19.5708] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
66 Ong A, Wong VW, Wong GL, Chan HY, Tse CH, Chan HL. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Aliment Pharmacol Ther. 2011;34:972-981. [PMID: 21883327 DOI: 10.1111/j.1365-2036.2011.04833.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
67 Gallego A, Sheldon J, García-Samaniego J, Margall N, Romero M, Hornillos P, Soriano V, Enrĺquez J. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 2008;15:392-8. [PMID: 18221300 DOI: 10.1111/j.1365-2893.2007.00966.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
68 Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis. 2008;8:167-178. [PMID: 18053766 DOI: 10.1016/s1473-3099(07)70264-5] [Cited by in Crossref: 138] [Cited by in F6Publishing: 55] [Article Influence: 9.2] [Reference Citation Analysis]
69 Zarski JP. [Clinical case: treatment of chronic hepatitis B]. Gastroenterol Clin Biol 2009;33:358-60. [PMID: 19345534 DOI: 10.1016/j.gcb.2009.02.016] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis: EVALUATING ANTI-VIRAL THERAPY IN HBEAG-NEGATIVE CHB. Alimentary Pharmacology & Therapeutics 2008;27:1240-52. [DOI: 10.1111/j.1365-2036.2008.03691.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
71 Woo HY, Choi JY, Yoon SK, Suh DJ, Paik SW, Han KH, Um SH, Kim BI, Lee HJ, Cho M, Lee CK, Kim DJ, Hwang JS. Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. Clin Mol Hepatol 2014;20:168-76. [PMID: 25032183 DOI: 10.3350/cmh.2014.20.2.168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
72 Kim JH, Moon HW, Ko SY, Choe WH, Kwon SY. Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. Clin Mol Hepatol 2014;20:274-82. [PMID: 25320731 DOI: 10.3350/cmh.2014.20.3.274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Lee KS, Kim DJ; Guideline Committee of the Korean Association for the Study of the Liver. Management of Chronic Hepatitis B. Korean J Hepatol 2007;13:447. [DOI: 10.3350/kjhep.2007.13.4.447] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
74 Son CY, Ryu HJ, Lee JM, Ahn SH, Kim DY, Lee MH, Han KH, Chon CY, Park JY. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. Liver Int 2012;32:1179-85. [DOI: 10.1111/j.1478-3231.2012.02793.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
75 Srivastava M, Singh N, Dixit VK, Nath G, Jain AK. Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study. Indian J Med Res 2016;144:424-32. [PMID: 28139541 DOI: 10.4103/0971-5916.198674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
76 Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clinical Gastroenterology and Hepatology 2008;6:1315-41. [DOI: 10.1016/j.cgh.2008.08.021] [Cited by in Crossref: 315] [Cited by in F6Publishing: 289] [Article Influence: 22.5] [Reference Citation Analysis]
77 Shakado S, Watanabe H, Tanaka T, Morihara D, Nishizawa S, Inomata S, Ueda S, Matsumoto T, Anan A, Takeyama Y, Irie M, Iwata K, Sohda T, Sakisaka S. Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B. Hepatol Int 2008;2:361-9. [PMID: 19669266 DOI: 10.1007/s12072-008-9081-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
78 Choe WH, Kwon SY, Kim BK, Ko SY, Yeon JE, Byun KS, Kim G, Lee CH. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis: Tenofovir plus lamivudine against adefovir-resistant HBV. Liver International 2008;28:814-20. [DOI: 10.1111/j.1478-3231.2008.01685.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
79 Zhao P, Wang C, Huang L, Xu D, Li T. Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. Antiviral Res. 2012;96:100-104. [PMID: 22960601 DOI: 10.1016/j.antiviral.2012.08.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
80 Hadziyannis SJ. Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B. Aliment Pharmacol Ther 2012;35:1482. [PMID: 22582839 DOI: 10.1111/j.1365-2036.2012.05105.x] [Reference Citation Analysis]
81 Jung YJ, Kim BG, Kim JS, Kim W, Yoon JH, Lee HS, Yi NJ, Lee KW, Suh KS, Kim YJ. The effect of pretransplantation lamivudine resistance on the prognosis of liver transplant recipients. Transplant Proc 2013;45:231-5. [PMID: 23375306 DOI: 10.1016/j.transproceed.2012.06.078] [Reference Citation Analysis]
82 Liu F, Wang X, Wei F, Hu H, Zhang D, Hu P, Ren H. Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis. Virol J. 2014;11:59. [PMID: 24673792 DOI: 10.1186/1743-422x-11-59] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
83 Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8:275-284. [PMID: 21423260 DOI: 10.1038/nrgastro.2011.33] [Cited by in Crossref: 171] [Cited by in F6Publishing: 165] [Article Influence: 15.5] [Reference Citation Analysis]
84 Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int. 2013;33:244-254. [PMID: 23295056 DOI: 10.1111/liv.12036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
85 Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48:99-108. [PMID: 18537189 DOI: 10.1002/hep.22323] [Cited by in Crossref: 122] [Cited by in F6Publishing: 110] [Article Influence: 8.7] [Reference Citation Analysis]
86 Di Marco V, Craxì A. Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev Anti Infect Ther 2009;7:281-91. [PMID: 19344242 DOI: 10.1586/eri.09.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
87 Chu M, Cho SM, Choe BH, Cho MH, Kwon S, Lee WK. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. J Pediatr Gastroenterol Nutr. 2012;55:648-652. [PMID: 22688509 DOI: 10.1097/mpg.0b013e318262a737] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
88 Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008;26:937-49. [PMID: 18850763 DOI: 10.2165/00019053-200826110-00006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
89 Brunetto MR, Colombatto P, Bonino F. Personalized therapy in chronic viral hepatitis. Mol Aspects Med 2008;29:103-11. [PMID: 18068759 DOI: 10.1016/j.mam.2007.09.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
90 Shin SR, Koh KC, Gwak GY, Choi MS, Lee JH, Paik SW, Yoo BC. A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B. J Gut Liver. 2010;4:530-536. [PMID: 21253304 DOI: 10.5009/gnl.2010.4.4.530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
91 Gaia S, Barbon V, Smedile A, Olivero A, Carenzi S, Lagget M, Alessandria C, Rizzetto M, Marzano A. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol. 2008;48:540-547. [PMID: 18279995 DOI: 10.1016/j.jhep.2007.12.018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
92 Yim HJ. Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B? Clin Mol Hepatol 2016;22:238-40. [PMID: 27377908 DOI: 10.3350/cmh.2016.0103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
93 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
94 Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up. Journal of Hepatology 2008;48:923-31. [DOI: 10.1016/j.jhep.2008.02.019] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
95 Park JG, Park SY. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. Clin Mol Hepatol 2015;21:242-8. [PMID: 26523269 DOI: 10.3350/cmh.2015.21.3.242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
96 Brunetto MR. Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance. Journal of Hepatology 2007;46:756-8. [DOI: 10.1016/j.jhep.2007.02.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
97 Park JY, Kim CW, Bae SH, Jung KS, Kim HY, Yoon SK, Han KH, Ahn SH. Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. Liver Int 2016;36:1108-15. [PMID: 26781724 DOI: 10.1111/liv.13059] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
98 Ko SY, Oh HB, Park CW, Lee HC, Lee JE. Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing. Clin Microbiol Infect. 2012;18:E404-E411. [PMID: 22757653 DOI: 10.1111/j.1469-0691.2012.03951.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
99 Lim YS. Management of Antiviral Resistance in Chronic Hepatitis B. Gut Liver 2017;11:189-95. [PMID: 28183162 DOI: 10.5009/gnl15562] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
100 Liaw Y. Rescue therapy for lamivudine-resistant chronic hepatitis B: When and how? Hepatology 2007;45:266-8. [DOI: 10.1002/hep.21546] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
101 Liaw Y, Chu C. Hepatitis B virus infection. The Lancet 2009;373:582-92. [DOI: 10.1016/s0140-6736(09)60207-5] [Cited by in Crossref: 833] [Cited by in F6Publishing: 366] [Article Influence: 64.1] [Reference Citation Analysis]
102 Lin CL, Kao JH. Hepatitis B viral factors and treatment responses in chronic hepatitis B. J Formos Med Assoc. 2013;112:302-311. [PMID: 23787007 DOI: 10.1016/j.jfma.2013.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
103 Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348-356. [PMID: 20483498 DOI: 10.1016/j.jhep.2010.02.035] [Cited by in Crossref: 289] [Cited by in F6Publishing: 272] [Article Influence: 24.1] [Reference Citation Analysis]
104 Yim HJ, Hwang SG. Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol. 2013;19:195-209. [PMID: 24133659 DOI: 10.3350/cmh.2013.19.3.195] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
105 Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, T Kennedy P, Dusheiko G, Hill-Cawthorne G, Thomas H. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom. Value Health 2015;18:800-9. [PMID: 26409607 DOI: 10.1016/j.jval.2015.05.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
106 Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Casado MÁ, Jorquera F, the TENOSIMP-B Research Group. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World J Gastroenterol 2017; 23(41): 7459-7469 [PMID: 29151700 DOI: 10.3748/wjg.v23.i41.7459] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
107 Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H. Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol. 2007;79:1811-1817. [PMID: 17935165 DOI: 10.1002/jmv.20981] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
108 Kim SS, Cheong JY, Cho SW. Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver 2011;5:278-87. [PMID: 21927654 DOI: 10.5009/gnl.2011.5.3.278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
109 Chen EQ, Wang LC, Lei J, Xu L, Tang H. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J. 2009;6:163. [PMID: 19818142 DOI: 10.1186/1743-422x-6-163] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
110 Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol 2012;47:577-85. [PMID: 22231575 DOI: 10.1007/s00535-011-0522-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
111 Feitelson MA, Clayton MM, Reis HM, Wu G, Lu EP. Pharmacotherapy of chronic viral hepatitis and hepatocellular carcinoma. Expert Opin Pharmacother 2008;9:2233-45. [PMID: 18710349 DOI: 10.1517/14656566.9.13.2233] [Reference Citation Analysis]
112 Yang HJ, Lee JH, Kim YJ, Yoon JH, Lee HS. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance. J Med Virol. 2012;84:424-430. [PMID: 22246827 DOI: 10.1002/jmv.23229] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
113 Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011;34:1145-1158. [PMID: 21978243 DOI: 10.1111/j.1365-2036.2011.04869.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
114 Lin MT, Yen YH, Tsai MC, Tseng PL, Chang KC, Wu CK, Hu TH. Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice. PLoS One 2016;11:e0165416. [PMID: 27806120 DOI: 10.1371/journal.pone.0165416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
115 Nash KL, Alexander GJ. The case for combination antiviral therapy for chronic hepatitis B virus infection. Lancet Infect Dis 2008;8:444-8. [PMID: 18485825 DOI: 10.1016/S1473-3099(08)70102-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
116 Chen CH, Lee CM, Tung WC, Wang JH, Hung CH, Hu TH, Wang JC, Lu SN, Changchien CS. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatol 2010;52:478-85. [PMID: 20185198 DOI: 10.1016/j.jhep.2010.01.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
117 Gao X, Liu W, Zhang X, Tang L, Wang L, Yan L, Yang H, Li T, Yang L, Ma N, Liu D. Genetic polymorphism of HLA-DQ confers susceptibility to hepatitis B virus-related hepatocellular carcinoma: a case-control study in Han population in China. Tumour Biol 2016;37:12103-11. [PMID: 27209411 DOI: 10.1007/s13277-016-5077-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
118 Osborn M. Hepatitis B in HIV: available treatment options and approach to therapy. Curr Infect Dis Rep 2009;11:407-13. [PMID: 19698285 DOI: 10.1007/s11908-009-0057-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
119 Sinn DH, Lee HI, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Virological response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol 2011; 17(30): 3526-3530 [PMID: 21941420 DOI: 10.3748/wjg.v17.i30.3526] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
120 Mahabadi M, Alavian SM, Norouzi M, Keyvani H, Mahmoudi M, Jazayeri SM. Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B. Electron Physician 2016;8:2466-74. [PMID: 27504160 DOI: 10.19082/2466] [Reference Citation Analysis]
121 de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, Ono SK. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol 2020;55:496-514. [PMID: 32185517 DOI: 10.1007/s00535-020-01680-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
122 Marcellin P, Cadranel JF, Fontanges T, Poynard T, Pol S, Trepo C, Blin P, Bregman B, Schmidely N, Roudot-Thoraval F, Zarski JP. High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients. Eur J Gastroenterol Hepatol 2010;22:1290-6. [PMID: 20964259 DOI: 10.1097/meg.0b013e32832fba4f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
123 Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010;53:449-454. [PMID: 20646776 DOI: 10.1016/j.jhep.2010.03.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
124 Degertekin B, Lok AS. Update on viral hepatitis: 2007. Curr Opin Gastroenterol. 2008;24:306-311. [PMID: 18408458 DOI: 10.1097/mog.0b013e3282f70285] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
125 Jang BK. Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? Clin Mol Hepatol 2020;26:312-4. [PMID: 32646206 DOI: 10.3350/cmh.2020.0099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Di Marco V, Craxì A. Adefovir for lamivudine resistant HBV: More than meets the eye. Journal of Hepatology 2007;47:618-9. [DOI: 10.1016/j.jhep.2007.07.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
127 Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B: Lamivudine resistance. Hepatol Int. 2008;2:440-456. [PMID: 19669319 DOI: 10.1007/s12072-008-9105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Kim YJ, Paik SW, Sinn DH, Gwak G, Choi MS, Lee JH, Koh KC, Yoo BC. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance: Adefovir add-on in lamivudine-resistance. Journal of Gastroenterology and Hepatology 2012;27:1454-60. [DOI: 10.1111/j.1440-1746.2011.07050.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
129 Papatheodoridis GV, Deutsch M. Resistance issues in treating chronic hepatitis B. Future Microbiology 2008;3:525-38. [DOI: 10.2217/17460913.3.5.525] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
130 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
131 Takkenberg B, de Bruijne J, Weegink C, Jansen P, Reesink H. Novel therapies in hepatitis B and C. Curr Gastroenterol Rep 2008;10:81-90. [PMID: 18417047 DOI: 10.1007/s11894-008-0013-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
132 Noordeen F. Hepatitis B virus infection: An insight into infection outcomes and recent treatment options. Virusdisease 2015;26:1-8. [PMID: 26436115 DOI: 10.1007/s13337-015-0247-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
133 Liu W, Ma N, Gao X, Liu W, Jia J, Tang L, Li M, Yang L, Li T, Yan L, Zhang X, Yu F. Role of GSPT1 and GSPT2 polymorphisms in different outcomes upon Hepatitis B virus infection and prognosis to lamivudine therapy. Biosci Rep 2019;39:BSR20181668. [PMID: 30867251 DOI: 10.1042/BSR20181668] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
134 Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, Chutaputti A, Rasenack J, Hou J, O’Brien C. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 2009;51:11-20. [PMID: 19345439 DOI: 10.1016/j.jhep.2008.12.019] [Cited by in Crossref: 154] [Cited by in F6Publishing: 154] [Article Influence: 11.8] [Reference Citation Analysis]
135 Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445-1451. [PMID: 17983801 DOI: 10.1053/j.gastro.2007.08.079] [Cited by in Crossref: 230] [Cited by in F6Publishing: 211] [Article Influence: 15.3] [Reference Citation Analysis]
136 Gao X, Liu W, Yang L, Zhang X, Ma N, Wang L, Yan L, Tang L, Yang H, Liu D. Association between PNPLA3 gene polymorphisms and risk of hepatitis B virus-related hepatocellular carcinoma in Han population in China:a case-control study. Scand J Gastroenterol 2017;52:1120-7. [PMID: 28617615 DOI: 10.1080/00365521.2017.1334088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
137 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol 2012; 18(48): 7149-7157 [PMID: 23326119 DOI: 10.3748/wjg.v18.i48.7149] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
138 Kwak MS, Choi JW, Lee JS, Kim KA, Suh JH, Cho YS, Won SY, Park BK, Lee CK. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir. J Viral Hepat. 2011;18:e432-e438. [PMID: 21914060 DOI: 10.1111/j.1365-2893.2011.01461.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
139 Lopez-Suñé E, Tuset M, Laguno M, Moreno A, Miró JM. [Characteristics of hepatitis and influenza antivirals: update 2009]. Enferm Infecc Microbiol Clin 2010;28:253.e1-17. [PMID: 20395018 DOI: 10.1016/j.eimc.2010.02.001] [Reference Citation Analysis]
140 Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: Preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol. 2008;6:268-274. [PMID: 18328434 DOI: 10.1016/j.cgh.2007.12.043] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.4] [Reference Citation Analysis]
141 Min AD, Dienstag JL. Oral antivirals for chronic hepatitis B. Clin Liver Dis 2007;11:851-68, ix. [PMID: 17981232 DOI: 10.1016/j.cld.2007.08.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
142 Wong CR, Trinh HN, Yip B, Nguyen HA, Garcia RT, Ahmed A, Keeffe EB, Nguyen MH. High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure. Journal of Clinical Gastroenterology 2011;45:900-5. [DOI: 10.1097/mcg.0b013e318224d64f] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
143 Gupta N, Goyal M, Wu CH, Wu GY. The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. J Clin Transl Hepatol. 2014;2:202-211. [PMID: 26357626 DOI: 10.14218/jcth.2014.00021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
144 Kim MN, Lee CK, Ahn SH, Lee S, Kim SU, Kim DY, Kim HS, Han KH, Chon CY, Park JY. Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. Liver Int 2014;34:1543-9. [PMID: 24330475 DOI: 10.1111/liv.12437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
145 Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009;18:1655-1666. [PMID: 19852566 DOI: 10.1517/13543780903241599] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
146 Yen YH, Lu SN, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS, Lee CM. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy. Liver Int 2007;27:1349-55. [PMID: 18036099 DOI: 10.1111/j.1478-3231.2007.01609.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
147 Lee SJ, Yim HJ, Hwang SG, Seo YS, Kim JH, Yoon EL, Lee JM, Kim BH, Park SJ, Park YM, Kim HS, Lee SH, Ahn SH, Lee JI, Lee JW, Kim IH, Kim HS, Hong SP. Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. Scand J Gastroenterol 2013;48:196-204. [PMID: 23194375 DOI: 10.3109/00365521.2012.722671] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
148 Kim JH, Ko SY, Choe WH, Kwon SY, Lee CH. Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. Clin Mol Hepatol. 2013;19:273-279. [PMID: 24133665 DOI: 10.3350/cmh.2013.19.3.273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
149 Zhao WF, Shao YL, Chen LY, Wu JH, Zhu YL, Gan JH, Xiong H. Establishment of a new quantitative detection approach to adefovir-resistant HBV and its clinical application. World J Gastroenterol 2010; 16(10): 1267-1273 [PMID: 20222172 DOI: 10.3748/wjg.v16.i10.1267] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
150 Wu S, Fukai K, Imazeki F, Arai M, Kanda T, Yonemitsu Y, Yokosuka O. Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B. Dig Dis Sci. 2011;56:1207-1214. [PMID: 20927588 DOI: 10.1007/s10620-010-1423-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
151 Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009;49:S122-8. [DOI: 10.1002/hep.22921] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
152 Menne S, Butler SD, George AL, Tochkov IA, Zhu Y, Xiong S, Gerin JL, Cote PJ, Tennant BC. Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2008;52:3617-3632. [PMID: 18676881 DOI: 10.1128/aac.00654-08] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
153 Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N, Mpoumponaris A, Gkisakis D, Theodoropoulos K, Panderi A, Katsinelos P, Eugenidis N. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg - chronic hepatitis B patients: A 4-year study. Journal of Gastroenterology and Hepatology 2010;25:54-60. [DOI: 10.1111/j.1440-1746.2009.05952.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
154 Ryu HJ, Lee JM, Ahn SH, Kim do Y, Lee MH, Han KH, Chon CY, Park JY. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol. 2010;82:1835-1842. [PMID: 20872709 DOI: 10.1002/jmv.21898] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
155 Lui YY, Chan HL. A review of telbivudine for the management of chronic hepatitis B virus infection. Expert Opinion on Drug Metabolism & Toxicology 2008;4:1351-61. [DOI: 10.1517/17425255.4.10.1351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
156 Kim J, Lee SH, Kim HS, Choi K, Jeong SW, Kim SG, Jang JY, Kim YS, Kim BS. Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B. Gut Liver 2015;9:103-8. [PMID: 25287170 DOI: 10.5009/gnl14018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
157 Kumar M, Sarin SK. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;2:465-95. [DOI: 10.1586/17474124.2.4.465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
158 Ding X, Yang J, Wang S. Antisense Oligonucleotides Targeting Abhydrolase Domain Containing 2 Block Human Hepatitis B Virus Propagation. Oligonucleotides 2011;21:77-84. [DOI: 10.1089/oli.2011.0280] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
159 Aizawa M, Tsubota A, Fujise K, Tatsuzawa K, Kono M, Hoshina S, Tajiri H. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. J Med Virol 2011;83:953-61. [DOI: 10.1002/jmv.22025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
160 Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014;44 Suppl S1:1-58. [PMID: 24397839 DOI: 10.1111/hepr.12269] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 12.9] [Reference Citation Analysis]
161 Lee YB, Jung EU, Kim BH, Lee JH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B. Antimicrob Agents Chemother. 2015;59:972-978. [PMID: 25421484 DOI: 10.1128/AAC.04454-14] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
162 Ikeda F, Baba N, Takaguchi K, Kubota J, Miyoshi K, Fujioka S, Moritou Y, Takeuchi Y, Yasunaka T, Miyake Y, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K. Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance. J Med Virol 2012;84:1562-70. [PMID: 22930504 DOI: 10.1002/jmv.23371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
163 Lampertico P, Colombo M. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues. Liver Int 2009;29 Suppl 1:130-2. [PMID: 19207976 DOI: 10.1111/j.1478-3231.2008.01931.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
164 Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients. Antimicrob Agents Chemother. 2013;57:3369-3374. [PMID: 23650172 DOI: 10.1128/aac.00587-13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Buchanan C, Tran TT. Current status of liver transplantation for hepatitis B virus. Clin Liver Dis. 2011;15:753-764. [PMID: 22032527 DOI: 10.1016/j.cld.2011.08.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
166 Scott JD, Mcmahon B. Role of combination therapy in chronic hepatitis B. Curr Gastroenterol Rep 2009;11:28-36. [DOI: 10.1007/s11894-009-0005-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
167 Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. J Viral Hepat. 2009;16:279-285. [PMID: 19222742 DOI: 10.1111/j.1365-2893.2009.01074.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
168 Wang HL, Lu X, Yang X, Xu N. Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis. Gastroenterol Res Pract 2016;2016:3435965. [PMID: 27672391 DOI: 10.1155/2016/3435965] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
169 Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin Investig Drugs. 2007;16:777-786. [PMID: 17501691 DOI: 10.1517/13543784.16.6.777] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
170 Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World J Gastroenterol 2015; 21(9): 2746-2753 [PMID: 25759545 DOI: 10.3748/wjg.v21.i9.2746] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
171 Okada M, Enomoto M, Kawada N, Nguyen MH. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol. 2017;11:1095-1104. [PMID: 28752768 DOI: 10.1080/17474124.2017.1361822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
172 Hann HW, Dunn SR, Ahn M, Park SY. Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009). J Med Virol 2010;82:1489-93. [PMID: 20648601 DOI: 10.1002/jmv.21842] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
173 Chen EQ, Bai L, Chen LL, Zhou TY, Du LY, Tang H. Prolonged Combination Therapy is More Effective than Monotherapy in Management of Chronic Hepatitis B Patients With Sustained Virological Response: An Experience From a 'Real-World' Clinical Setting. Iran Red Crescent Med J 2013;15:e7788. [PMID: 24693412 DOI: 10.5812/ircmj.7788] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
174 Chien RN, Liaw YF. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 2008;22:1081-92. [PMID: 19187868 DOI: 10.1016/j.bpg.2008.11.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
175 Sheng YJ, Liu JY, Tong SW, Hu HD, Zhang DZ, Hu P, Ren H. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J. 2011;8:393. [PMID: 21824397 DOI: 10.1186/1743-422x-8-393] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 3.9] [Reference Citation Analysis]
176 Cai Q, Chen K, Chen J, Wu S, Geng Q, Huang H, Lin T, Jiang W, Xia Z, Duan H, Rao H, Yao M, Hu L. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. PLoS One 2016;11:e0164210. [PMID: 27711135 DOI: 10.1371/journal.pone.0164210] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
177 Rapti IN, Hadziyannis SJ. Treatment of special populations with chronic hepatitis B infection. Expert Review of Gastroenterology & Hepatology 2014;5:323-39. [DOI: 10.1586/egh.11.7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
178 Wang LC, Chen EQ, Zhu XF, Xiong ZH, Liu L, Xu L, Lei XZ, Liu C, Tang H. Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve chronic hepatitis B patients at 48 weeks. Gut Liver. 2011;5:478-485. [PMID: 22195247 DOI: 10.5009/gnl.2011.5.4.478] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
179 Asselah T, Lada O, Boyer N, Martinot M, Marcellin P. [Treatment of chronic hepatitis B]. Gastroenterol Clin Biol. 2008;32:749-768. [PMID: 18775613 DOI: 10.1016/j.gcb.2008.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
180 Kim M, Jung SW, Shin JW, Park NH. The Level of HBV DNA at Month 12 Is an Important Predictor of Virological Breakthrough During Adefovir Monotherapy in Chronic Hepatitis B Patients with Lamivudine Resistance. Dig Dis Sci 2011;56:1215-21. [DOI: 10.1007/s10620-010-1537-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
181 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3] [Cited by in Crossref: 636] [Cited by in F6Publishing: 661] [Article Influence: 45.4] [Reference Citation Analysis]
182 Tan HH, Martin P. Management of end-stage liver disease in chronic hepatitis B. Clin Liver Dis. 2010;14:477-493. [PMID: 20638026 DOI: 10.1016/j.cld.2010.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
183 Lim YS, Byun KS, Yoo BC, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 2016;65:852-860. [PMID: 25596179 DOI: 10.1136/gutjnl-2014-308353] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 7.9] [Reference Citation Analysis]
184 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 660] [Article Influence: 69.5] [Reference Citation Analysis]
185 Park JH, Jung SW, Park NH, Park BR, Kim MH, Kim CJ, Lee BU, Jeong ID, Kim BG, Bang SJ. Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. Clin Ther. 2015;37:1433-1442. [PMID: 25956353 DOI: 10.1016/j.clinthera.2015.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
186 Choi MS, Yoo BC. Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. Gut Liver 2010;4:15-24. [PMID: 20479908 DOI: 10.5009/gnl.2010.4.1.15] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
187 Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14(45): 6902-6910 [PMID: 19058323 DOI: 10.3748/wjg.14.6902] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
188 Ide T, Sata M, Chayama K, Shindo M, Toyota J, Mochida S, Tomita E, Kumada H, Yamada G, Yatsuhashi H, Hayashi N, Ishikawa H, Seriu T, Omata M. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. Hepatol Int 2010;4:594-600. [PMID: 21063482 DOI: 10.1007/s12072-010-9185-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
189 Holness G, Carriero DC, Dieterich DT. Hepatitis B therapies and antiviral resistance detection and management. Expert Review of Gastroenterology & Hepatology 2014;3:693-9. [DOI: 10.1586/egh.09.64] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
190 Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-frias F, Schapper M, Bonovas S, Esteban R. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. Journal of Hepatology 2007;47:366-72. [DOI: 10.1016/j.jhep.2007.04.011] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 4.0] [Reference Citation Analysis]
191 Liu W, Ma N, Zhao D, Gao X, Zhang X, Yang L, Liu D. Correlation between the DEPDC5 rs1012068 polymorphism and the risk of HBV-related hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2019;43:446-50. [PMID: 30683632 DOI: 10.1016/j.clinre.2018.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
192 Moon JC, Kim SH, Kim IH, Lee CH, Kim SW, Lee SO, Lee ST, Kim DG. Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy. Gut Liver. 2015;9:395-404. [PMID: 25473072 DOI: 10.5009/gnl14170] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
193 Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother. 2012;56:2941-2947. [PMID: 22430972 DOI: 10.1128/aac.00338-12] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
194 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15(20): 2489-2499 [PMID: 19468999 DOI: 10.3748/wjg.15.2489] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
195 Viganò M, Lampertico P, Colombo M. Drug safety evaluation of adefovir in HBV infection. Expert Opin Drug Saf. 2011;10:809-818. [PMID: 21671843 DOI: 10.1517/14740338.2011.593507] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
196 Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance. Hepatol Int 2008;2:440-56. [PMID: 19669319 DOI: 10.1007/s12072-008-9105-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
197 Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49:S174-S184. [PMID: 19399794 DOI: 10.1002/hep.22900] [Cited by in Crossref: 142] [Cited by in F6Publishing: 140] [Article Influence: 10.9] [Reference Citation Analysis]
198 Kim DY, Park JY. Step-down strategy in antiviral resistant chronic hepatitis B patients who achieved viral suppression with rescue combination therapy. Future Virology 2018;13:711-7. [DOI: 10.2217/fvl-2018-0078] [Reference Citation Analysis]
199 Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, Marks P, Goodman Z, Philp FH, Tang Y, Locarnini S, Thio CL. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS. 2009;23:1707-1715. [PMID: 19584701 DOI: 10.1097/qad.0b013e32832b43f2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
200 Lai HW, Chang CC, Chen TH, Tsai MC, Chen TY, Lin CC. Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients. J Formos Med Assoc. 2012;111:439-444. [PMID: 22939662 DOI: 10.1016/j.jfma.2011.05.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
201 Chen Y, Liaw Y. Pharmacotherapeutic options for hepatitis B. Expert Opinion on Pharmacotherapy 2016;17:355-67. [DOI: 10.1517/14656566.2016.1118056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
202 Park H, Park JY, Kim SU, Kim DY, Han KH, Chon CY, Ahn SH. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. World J Gastroenterol 2013; 19(43): 7671-7679 [PMID: 24431895 DOI: 10.3748/wjg.v19.i43.7671] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
203 Bhattacharya D, Thio CL. Review of hepatitis B therapeutics. Clin Infect Dis. 2010;51:1201-1208. [PMID: 20954965 DOI: 10.1086/656624] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
204 Cho JH, Cheong JY, Kang JK, Park JS, Lee MH, Lim NK, Hong SP, Kim S, Yoo WD, Cho SW. Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol 2008;14:58. [DOI: 10.3350/kjhep.2008.14.1.58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
205 Woo HY, Park JY, Bae SH, Kim CW, Jang JY, Tak WY, Kim DJ, Kim IH, Heo J, Ahn SH. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. Clin Mol Hepatol 2020;26:352-63. [PMID: 32460460 DOI: 10.3350/cmh.2019.0044n] [Reference Citation Analysis]
206 Fan J, Zhang Y, Xiong H, Wang Y, Guo X. Nucleotide analogue-resistant mutations in hepatitis B viral genomes found in hepatitis B patients. J Gen Virol. 2015;96:663-670. [PMID: 25481755 DOI: 10.1099/jgv.0.000010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
207 Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis. 2009;9:256-264. [PMID: 19324298 DOI: 10.1016/s1473-3099(09)70056-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
208 Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. World J Gastroenterol 2012; 18(47): 6996-7002 [PMID: 23322999 DOI: 10.3748/wjg.v18.i47.6996] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
209 Kim JK, Lee HJ, Lee YJ, Chun JY, Lee IK, Lim YS, Suh DJ, Ko SY, Kim MH, Oh HB. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. J Virol Methods. 2008;149:76-84. [PMID: 18291537 DOI: 10.1016/j.jviromet.2008.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
210 Kurashige N, Hiramatsu N, Ohkawa K, Yakushijin T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Oshita M, Mita E, Hagiwara H, Nagase T, Yoshihara H, Hayashi E, Imai Y, Kato M, Kashihara T, Hayashi N. Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol 2009;44:601-7. [PMID: 19387534 DOI: 10.1007/s00535-009-0038-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
211 Wang F, Wang H, Shen H, Meng C, Weng X, Zhang W. Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues. Clin Ther. 2009;31:360-366. [PMID: 19302908 DOI: 10.1016/j.clinthera.2009.02.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
212 Heo J, Ahn SH, Kweon YO, Kim BH, Chan HL, Horban A, Wongcharatrawee S, Llamoso C, Lee KS. Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. J Gastroenterol Hepatol 2014;29:1485-93. [PMID: 25587617 DOI: 10.1111/jgh.12567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
213 Du X, Wang J, Shao L, Hu X, Yang C, Shen L, Weng X, Zhang W. Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels. J Viral Hepat. 2013;20:328-335. [PMID: 23565615 DOI: 10.1111/jvh.12034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
214 Gonzalez SA, Keeffe EB. Chronic hepatitis B and C: update on therapy. Future Virology 2009;4:437-52. [DOI: 10.2217/fvl.09.43] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
215 Osborn MK, Han SH, Regev A, Bzowej NH, Ishitani MB, Tran TT, Lok AS. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol. 2007;5:1454-1461. [PMID: 17977800 DOI: 10.1016/j.cgh.2007.08.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
216 Wang HL, Lu X, Yang X, Ning Q. Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015; Nov 24. [Epub ahead of print]. [PMID: 26621535 DOI: 10.1016/j.clinre.2015.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
217 Wang T, Qin Y, Zhang J, Li X, Tong S, Zhao W, Zhang J. An antiviral drug-resistant mutant of hepatitis B virus with high replication capacity in association with a large in-frame deletion in the preS1 region of viral surface gene. Virus Genes 2020;56:677-86. [PMID: 32840739 DOI: 10.1007/s11262-020-01787-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
218 Zhang X, Jia J, Dong J, Yu F, Ma N, Li M, Liu X, Liu W, Li T, Liu D. HLA-DQ polymorphisms with HBV infection: different outcomes upon infection and prognosis to lamivudine therapy. J Viral Hepat. 2014;21:491-498. [PMID: 24750255 DOI: 10.1111/jvh.12159] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
219 Joo MK, Yeon JE, Kim JH, Jung YK, Lee SJ, Kim JH, Yim HJ, Byun KS, Park JJ, Kim JS, Bak YT. Chronic cirrhotic hepatitis B patients with a high incidence of hepatic decompensation after viral breakthrough with lamivudine-resistant mutants and during rescue treatment. Scand J Gastroenterol 2008;43:1514-21. [PMID: 18663665 DOI: 10.1080/00365520802273033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
220 Lee J, Yoon J, Cho EJ, Yang HJ, Jang ES, Kwak M, Hwang SY, Yu SJ, Lee C, Kim YJ, Kim CY, Lee H. Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. Journal of Clinical Gastroenterology 2012;46:243-50. [DOI: 10.1097/mcg.0b013e318225f559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
221 Inoue J, Ueno Y, Wakui Y, Niitsuma H, Fukushima K, Yamagiwa Y, Shiina M, Kondo Y, Kakazu E, Tamai K. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J Viral Hepat. 2011;18:206-215. [PMID: 20367795 DOI: 10.1111/j.1365-2893.2010.01301.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
222 Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl. 2009;15:413-420. [PMID: 19326401 DOI: 10.1002/lt.21712] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
223 Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV therapy. Viruses 2009;1:484-509. [PMID: 21994557 DOI: 10.3390/v1030484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
224 Kahloun A, Bourlière M, Zoulim F. [Analogs combination therapy in chronic hepatitis B: when and how?]. Gastroenterol Clin Biol 2010;34 Suppl 2:S126-35. [PMID: 21095516 DOI: 10.1016/S0399-8320(10)70032-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
225 Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2008;23:1182-1192. [PMID: 18637060 DOI: 10.1111/j.1440-1746.2008.05400.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]